Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.50 |
| ▸ | LAP3 | P28838 | 3/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.45 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.45 |
| ▸ | GRN | P28799 | 1/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27828839 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL8188102 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Benzene SCHEMBL28285392 | 0.96 | ALDH1A1 (0.56) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL8219449 | 0.85 | TSHR (0.52) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL8373321 | 0.83 | TSHR (0.50) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL8373322 | 0.83 | TSHR (0.50) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL29820642 | 0.81 | TAS1R3 (0.55) | TSHRFOLH1 | |
| SCHEMBL21367972 | 0.81 | TAS1R3 (0.55) | TSHRFOLH1 | |
| SCHEMBL31139963 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL4599325 | 0.80 | TSHR (0.50) | ALDH1A1MAPTTSHRFOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118892583-B | High-wet tissue adhesion anti-swelling conductive hydrogel and preparation method thereof | 西安交通大学 | 2026-05-12 | — | — | CN | claimed |
| CN-115612014-B | Biological tissue adhesive capable of being adhered when meeting water and preparation method thereof | 西安交通大学 | 2024-02-13 | — | — | CN | claimed |
| CN-115612014-A | Biological tissue adhesive capable of adhering immediately when meeting water and preparation method thereof | 西安交通大学 | 2023-01-17 | — | — | CN | claimed |
| CN-115414520-A | Self-gel styptic powder and preparation method and application thereof | 西安交通大学 | 2022-12-02 | — | — | CN | claimed |
| CN-110684150-B | Amino acid nano hydrogel and preparation method and application thereof | 南方医科大学 | 2021-05-11 | — | — | CN | claimed |
| CN-112142911-A | High-toughness hydrogel based on amino acid acrylamide derivative and preparation method thereof | 西安交通大学 | 2020-12-29 | — | — | CN | claimed |
| CN-110684150-A | Amino acid nano hydrogel and preparation method and application thereof | 南方医科大学 | 2020-01-14 | — | — | CN | claimed |
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | claimed |
| JP-2008525522-A | — | — | 2008-07-17 | — | — | JP | claimed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | claimed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | claimed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| CN-118892583-B | High-wet tissue adhesion anti-swelling conductive hydrogel and preparation method thereof | 西安交通大学 | 2026-05-12 | — | — | CN | disclosed |
| CN-114096560-B | Sugar purification | 默克专利股份公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-118892583-A | High-wet tissue adhesion anti-swelling conductive hydrogel and preparation method thereof | 西安交通大学 | 2024-11-05 | — | — | CN | disclosed |
| CN-114007737-B | Antibody drug conjugate purification | 默克专利股份公司 | 2024-07-05 | — | — | CN | disclosed |
| US-6046289-A | FOR INHIBITING COAGULATION OF BLOOD PLATELETS, INHIBITING ADHESION OF ANIMAL CELLS, OR AS SUBSTRATE FOR CULTURING ANIMAL CELLS | FUJIFILM CORPORATION (JP) | 2000-04-04 | — | — | US | disclosed |
| EP-0488258-B1 | Propenamide derivatives, polymers, copolymers and use thereof | FUJI PHOTO FILM CO LTD (JP) | 1996-04-17 | — | — | EP | disclosed |
| EP-0488258-A2 | Propenamide derivatives, polymers, copolymers and use thereof | FUJI PHOTO FILM CO., LTD. (JP) | 1992-06-03 | — | — | EP | disclosed |
| US-4439545-A | Acrylic copolymers of N-acryloylpolymethyleneimines or N-acryloyldialkylamides, N,N'-acryloyldiaminoalcanes and N-acryloylaminoacids (or esters) their preparation and use as cation exchangers | SOCIETE D "EXPANSION SCIENTIFIQUE "EXPANSIA" (FR) | 1984-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ALDH1A1 2222/4885MEN1 822/4885LMNA 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.